Pure Global
NCT06402487

Propionic Acid in Multiple Sclerosis

Propionic Acid in Multiple Sclerosis - a Placebo-controlled Randomized Double-blinded Clinical Trial
Salzburger Landeskliniken·Phase 2/3·ClinicalTrials.gov·dietary supplementEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Sclerosis
Drug/Device/Intervention
Propionic acid 1000 mg capsule
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
Salzburger Landeskliniken
Location
Salzburg, Austria
Timeline & enrollment
Phase
Phase 2/3
Start date
May 01, 2024
End date
Oct 15, 2024
Enrollment
100 participants
Primary outcome

Serum neurofilament light chain (NfL),Serum glial fibrillary acid protein (GFAP)

Summary

The purpose of this study is to demonstrate the superiority of propionic acid over placebo as
 add on treatment in multiple sclerosis (MS).

ICD-10 classifications
Multiple sclerosisProgressive systemic sclerosisSystemic sclerosisSystemic sclerosis, unspecifiedDiffuse sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06402487
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06402487 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Salzburger Landeskliniken and is currently Enrolling by invitation. The study focuses on Multiple Sclerosis. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.